Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc.

TMO
Thermo Fisher Scientific Inc.US flagNew York Stock Exchange
568.26
USD
-4.06
- -
211.18BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
36.33
42.41
42.55
46.29
52.96
60.59
63.86
81.36
99.52
114.58
111.03
112.25
118.19
91.76
Basic EPS, GAAP
3.53
4.76
4.95
5.12
5.63
7.31
9.24
16.1
19.61
17.73
15.53
16.58
17.78
13.98
Free Cash Flow per Basic Share
4.8
5.5
6.32
7.13
8.85
9.42
10.12
17.21
17.23
17.63
17.95
19.02
16.69
15.08
Dividend per Share
0.6
0.59
0.6
0.6
0.6
0.66
0.74
0.85
1
1.16
1.35
1.53
1.69
1.3
Book Value per Share
25.32
27.16
31.49
36.33
41.37
47.58
56.32
72.1
91.04
108.04
123.85
140.17
158.09
- -
Tangible Book Value per Share
-7.55
-31.15
-25.67
-34.85
-41.93
-31.69
-25.13
-10.63
-53.45
-36.96
-35.88
-30.66
-30.94
- -
Basic Weighted Avg Shares
360
398
399
395
395
402
400
396
394
392
386
382
377
374
Sales/Revenue/Turnover
13,090
16,890
16,965
18,274
20,918
24,358
25,542
32,218
39,211
44,915
42,857
42,879
44,557
34,342
Operating Margin (%)
12.89
11.28
14.45
14.49
14.61
15.74
16.37
24.5
26.08
18.94
17.08
18
18.2
18.32
Depreciation Expense
1,000
1,685
1,688
1,758
2,033
2,267
2,277
2,325
2,592
3,381
3,406
3,108
2,780
2,125
Net Income, GAAP
1,273
1,894
1,975
2,022
2,225
2,938
3,696
6,375
7,725
6,950
5,995
6,335
6,704
5,231
Effective Tax Rate (%)
3.06
9.18
- -
- -
8.28
9.93
9.18
11.76
12.54
8.97
4.51
9.34
7.48
7.53
Profit Margin (%)
9.73
11.22
11.64
11.06
10.64
12.06
14.47
19.79
19.7
15.47
13.99
14.77
15.05
15.23
Working Capital
6,755
1,190
1,595
2,155
2,373
4,478
5,696
11,653
6,677
8,219
10,577
8,805
13,518
- -
LT Debt
9,500
12,352
11,420
15,372
18,873
17,719
17,076
19,107
32,333
28,909
31,308
29,061
35,852
- -
Total Equity
16,856
20,548
21,350
21,540
25,413
27,586
29,675
34,517
40,977
44,148
46,842
49,672
53,536
- -
Return on Invested Capital (%)
6.57
5.54
- -
- -
6.63
7.44
8.1
13.47
13.57
10.05
8.73
8.62
8.65
13.58
Return on Capital (%)
8.77
10.36
- -
- -
8.1
9.38
10.99
15.15
13.51
10.28
9.19
9.05
8.69
13.53
Return on Common Equity (%)
14.78
19
16.9
15.04
14.5
16.57
17.75
24.96
23.98
17.77
13.3
12.5
11.85
18.57

Capital Structure

FRC

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
3,533
3,090
- -
LT Borrowings
35,852
40,071
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
376
372
- -
Market Capitalization
218,742
184,815
187,634

Working Capital

FRC

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
28,707
22,316
- -
Cash, Cash Equivalents & STI
10,105
3,256
- -
Accounts Receivable, Net
8,900
9,204
- -
Inventories
5,425
5,496
- -
Total Current Liabilities
15,189
14,621
- -
Payables & Accruals
8,946
8,603
- -
ST Debt
3,533
3,090
- -
Deferred Revenue
2,710
2,928
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.77%
9.28%
7.78%
Free Cash Flow
11.27%
-1.37%
-13.4%
Net Income, GAAP
15.16%
1.78%
5.82%
Sales/Revenue/Turnover
10.53%
7.13%
3.91%
Total Cash Common Dividend
10.36%
13.58%
9.09%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
10,345
10,541
10,598
11,395
42,879
2025
10,364
10,854
11,122
12,215
44,557
2026
11,005
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3.48
4.05
4.27
4.79
16.58
2025
3.99
4.28
4.28
5.22
17.78
2026
4.44
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.35
0.39
0.39
0.39
1.53
2025
0.39
0.43
0.43
0.43
1.69
2026
0.44
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Marc N. Casper
Full Time Employees
125,000
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Address
168 Third Avenue Waltham MA United States of America 02451
IPO Date
Mar 17, 1980
Business
Thermo Fisher Scientific Inc. (NYSE: TMO) provides analytical instruments, equipment, software, services, consumables, and reagents for research, analysis, discovery, and diagnostics worldwide. The company offers products including mass spectrometry systems, chromatography instruments, genetic analysis tools, bioprocessing equipment, clinical diagnostics assays, laboratory automation solutions, and electron microscopy technologies; its key brands encompass Thermo Scientific, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon. Headquartered in Waltham, Massachusetts, Thermo Fisher was originally founded in 1902 through the merger of Fisher Scientific and Thermo Electron in 2006, and operates in over 70 countries serving pharmaceutical, biotechnology, academic, government, and healthcare customers across life sciences, analytical technologies, specialty diagnostics, and laboratory products segments. Recently, the company expanded its capabilities through the acquisition of Olink Holding AB in 2024 to bolster proteomics offerings, launched the new Orbitrap Astral mass spectrometer in late 2024 for high-throughput proteomics, and formed strategic partnerships including a multi-year collaboration with AstraZeneca to advance biomarker discovery; in 2025, Thermo Fisher announced expansions in gene editing technologies and sustainable manufacturing initiatives amid ongoing supply chain optimizations.

Company News

APIChatGPT
  • Thermo Fisher Scientific Launches Thermo Scientific™ InstaFlux™ to Help Food Microbiology Labs Simplify Workflows in Pathogen and Environmental Testing

  • Thermo Fisher Scientific Q2 Earnings Call Highlights

  • Thermo Fisher Scientific Inc. (TMO) Q2 2026 Earnings Call Transcript

  • Thermo Fisher Points to Improving End-Market Activity

  • TMO Q2 Earnings & Revenues Top Estimates, Stock Up in Pre-Market

  • Here's What Key Metrics Tell Us About Thermo Fisher (TMO) Q2 Earnings

  • Thermo Fisher Scientific (TMO) Surpasses Q2 Earnings and Revenue Estimates

  • Thermo Fisher beats quarterly estimates as customer demand improves

  • Thermo Fisher Scientific Reports Second Quarter 2026 Results

  • Acumen Wealth Advisors LLC Sells 2,166 Shares of Thermo Fisher Scientific Inc. $TMO

  • ImmuPharma picks Thermo Fisher to manufacture diabetes drug candidate

  • Andra AP fonden Purchases 53,990 Shares of Thermo Fisher Scientific Inc. $TMO

  • Exploring Analyst Estimates for Thermo Fisher (TMO) Q2 Earnings, Beyond Revenue and EPS

  • AIA Group Ltd Cuts Stock Holdings in Thermo Fisher Scientific Inc. $TMO

  • Thermo Fisher Set to Report Q2 Earnings: What's in the Cards?

  • TMO Fairly Valued by DCF at $478

  • Thermo Fisher Scientific Announces Quarterly Dividend

  • Thermo Fisher Q2 Preview: Buy Before The Recovery

  • Thermo Fisher Scientific Receives First FBI Approval for Rapid DNA Crime Scene Profiles Eligible for National CODIS Searches

  • Arcturus Picks Thermo Fisher To Support Cystic Fibrosis Therapy